iCAD ANNOUNCES MORE THAN 1,000 EARLY STAGE BREAST CANCER PATIENTS TREATED WITH INTRAOPERATIVE RADIATION THERAPY (IORT) USING THE XOFT SYSTEM

iCAD to Host Breast IORT Symposium and to Showcase Xoft System at 31st Annual Miami Breast Cancer Conference, Booth #22

NASHUA, N.H. and Miami– March 6, 2014 – iCAD, Inc. (Nasdaq: ICAD), a leading provider of advanced image analysis and radiation therapy solutions for the early identification and treatment of cancer, today announced at the 31st Annual Miami Breast Cancer Conference that more than 1,000 early stage breast cancer patients have been treated with Intraoperative Radiation Therapy (IORT) using the Xoft® Axxent® Electronic Brachytherapy System®. With IORT, a full course of radiation therapy is delivered to the patient in the operating room immediately following lumpectomy, replacing six to eight weeks of daily traditional radiation.

“The growing adoption and utilization of the Xoft System further validates that IORT is an attractive alternative for the treatment of early stage breast cancer because of its compelling benefits to patients,” said Ken Ferry, President and CEO of iCAD. “By offering IORT with the Xoft System, hospitals are able to expand their comprehensive breast care programs by providing appropriate patients with the option to complete a full dose of radiation therapy in a single treatment.”

“The Xoft System provides patients with a treatment option that helps mitigate the logistical burdens often associated with a traditional course of radiation treatment,” said Barbara Schwartzberg, M.D., Director of Breast Services, Sarah Cannon/HealthONE, Rose Medical Center. “IORT with the Xoft System delivers radiation directly into the tumor cavity while the patient is still under anesthesia, minimizing radiation exposure to surrounding healthy tissue. Because the treatment is delivered in one dose, my patients are able to maintain their quality of life and return to their jobs and families quickly.”

A post-market, prospective, multi-center, clinical trial evaluating the safety, efficacy and cosmetic outcomes associated with IORT for early-stage breast cancer with the Xoft System is currently underway at hospitals across the U.S.

iCAD to Host Lunch Symposium during Miami Breast Cancer Conference
On March 8, 2014, iCAD will host the Breast IORT Symposium: Clinical and Practice Perspectives from 1:00 p.m. EST – 2:15 p.m. EST at the Fontainebleau Miami Beach Hotel during the 31st Annual Miami Breast Cancer Conference taking place March 6 – March 9, 2014. Leading breast cancer surgeons will present and discuss their IORT clinical experience, which includes more than 400 patients. Topics will include IORT techniques, clinical advancements, scientific evidence, case review and IORT study protocol. The event is open to all conference attendees and the
public. For more details or to register, please visit: http://www.xoftinc.com/IORTsymposiumreg.html

iCAD will also showcase the Xoft System during the Miami Breast Cancer Conference at Booth #22.

About Xoft Axxent Electronic Brachytherapy System
The Xoft System is an isotope-free radiation treatment cleared by the U.S. Food and Drug Administration and CE marked in the EU for use anywhere in the body, including for the treatment of early-stage breast cancer, gynecological cancers and non-melanoma skin cancer. It utilizes a proprietary miniaturized x-ray as the radiation source that delivers precise treatment directly to cancerous areas while sparing healthy tissue and organs. The Xoft System requires only minimal shielding and therefore does not require room redesign or construction investment. Minimal shielding also allows medical personnel to remain in the room with the patient during treatment. The mobility of the Xoft System makes it easy to treat patients at multiple locations and to easily store the system when not in use. Xoft is a wholly owned subsidiary of iCAD, Inc. For more information about Xoft visit www.xoftinc.com, like us on Facebook or follow us on Twitter at @xofticad.

About iCAD, Inc.
iCAD is an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy solutions for the early identification and treatment of cancer. iCAD’s Xoft System offers radiation treatment for early-stage breast cancer that can be administered in the form of intraoperative radiation therapy or accelerated partial breast irradiation. The Xoft System is also cleared for the treatment of non-melanoma skin cancer and endometrial cancer. iCAD offers a comprehensive range of high-performance, upgradeable CAD solutions for mammography and advanced image analysis and workflow solutions for Magnetic Resonance Imaging, for breast and prostate cancers and Computed Tomography for colorectal cancer.

For iCAD, contact Kevin Burns at 937-431-7967 or via email at kburns@icadmed.com

For iCAD investor inquiries, contact Anne Marie Fields of LHA, 212-838-3777, afields@lhai.com

For iCAD media inquiries, contact Rachel Gross of MSLGROUP, 781-684-0770, icad@mslgroup.com

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the Company’s significant losses and uncertainty of our ability to achieve and sustain profitability, the ability to protect
patents and other proprietary rights, the ability to defend itself in litigation matters, the Company’s customers’ ability to obtain appropriate coverage, and reimbursement from third-party payors, for our products and treatments, the Company’s ability to create significant markets for its newly developed products and treatments, the Company’s dependence on a limited number of customers, the uncertainty of growth of the Company’s product markets, the risk of impairment of the Company’s goodwill or other intangible assets, the risks related to regulatory and other legal requirements, the significant costs of extensive regulatory compliance, the volatility of the Company’s operating and financial results, the risks related to the Company’s existing and future debt obligations, the possible technological obsolescence of the Company’s products, the impact of supply and manufacturing constraints or difficulties, competitive pressures and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “estimate”, “anticipate”, “likely”, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov

# # #